Summary:
HistoSonics' Edison uses ultrasound waves to non-invasively destroy tumors, turning tissue into liquid in minutes
FDA approved in 2023, already used in over 2,000 procedures across 50 U.S. hospitals
Expanding to treat kidney tumors and pancreatic cancer, with early results showing promise
$2.25 billion investment from Jeff Bezos and others, valuing the startup at a majority stake
CEO sees a $200 billion opportunity, with Minnesota as the permanent headquarters
HistoSonics, a med-tech startup based in Plymouth, Minnesota, is turning heads with its groundbreaking Edison robotic machine. This innovative device uses ultrasound waves to non-invasively target and destroy tumors, transforming solid tissue into liquid in under two minutes—a process vividly demonstrated with liver tissue.
How Edison Works
- Ultrasound Waves: Create a bubble cloud that destroys tissue at a sub-cellular level.
- Non-Invasive & Non-Toxic: Unlike radiation therapy, it can treat multiple tumors in one procedure.
FDA Approval & Traction
- FDA Approved in 2023 for liver tumors.
- Over 2,000 procedures completed.
- 50 U.S. hospitals have installed Edison, with 50 more on order, including Mayo Clinic and Abbott.
Beyond Liver Tumors
- Kidney Tumors: 15 centers completed enrollment; FDA submission expected next year.
- Pancreatic Cancer: Early results are "unbelievably encouraging," offering hope for improved quality of life.
Massive Investment
- A group including Jeff Bezos invested $2.25 billion for a majority stake.
- CEO Mike Blue envisions a $200 billion opportunity, with plans to expand clinical programs.
Future in Minnesota
- Moved from Ann Arbor to leverage Minnesota's med-tech ecosystem.
- Headquarters will remain in Minnesota, with ambitions for "industrial park domination."
Comments